Zynlonta

Product Overview

About Zynlonta

Zynlonta is a prescription medicine that should be started and supervised by a doctor with experience in using cancer medicines.

What it is used for

Not available in the provided information.

How it is used

Zynlonta is given as an infusion (drip) into a vein over 30 minutes every 3 weeks. Treatment can continue for as long as the patient benefits from it and does not have intolerable side effects. The dose depends on the patient’s body weight. If certain side effects develop, the doctor may decide to reduce the dose or to interrupt or stop treatment with Zynlonta. Before starting treatment, patients should be given dexamethasone (an anti-inflammatory medicine) to help reduce possible side effects of treatment.

How it works

In patients with B-cell lymphoma, B-cells (a type of white blood cell) have become cancerous. The active substance of Zynlonta, loncastuximab tesirine, is made up of a monoclonal antibody (a type of protein) combined with a cytotoxin (a substance that kills cells) called SG3199. The monoclonal antibody attaches to a protein called CD19 on the B-cells, including cancerous B-cells, and the medicine enters these cells. When Zynlonta is inside the B-cells, SG3199 is released and kills them.

Active substance: loncastuximab tesirine

Source: EMA EPAR